ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag books industry biotech publishing

Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Bland Blueprint for Biotech
George Poste | Apr 19, 1987 | 3 min read
Industrial Biotechnology in Europe: Issues for Public Policy. Duncan Davies, ed. Frances Pinter, London, 1986. 156 PP. £22.50. Distributed in North America by Longwood Publishing Group, Dover, NH. $30 HB, $14.50 PB. In 1967 Jean-Jacques Servan Schreiber published the instant best seller The American Challenge, which argued that Europe's weakness in high-technology industries could lead to economic stagnation and loss of political self-determination. Since this call for action, it has become
Women Make Their Mark As Top Executives In Biotech Industry
Ricki Lewis | Nov 23, 1997 | 8 min read
Being a company president-a job that entails handling day-to- day operations-or a chief executive officer (CEO)-who manages all aspects of a business-involves a unique combination of managerial skills. These roles are especially challenging for women, who are rare at corporate helms, particularly in the two-decade-old biotechnology industry. As biotech matures, the percentage of women at the top is growing. "Biotech is a relatively young industry. People are still working their way up. But we a
black and white photo of person onshore looking at orca in the water
Book Excerpt from Orca
Jason Colby | Jun 30, 2018 | 3 min read
In Chapter 15, author Jason Colby describes a scene of captive orca release and early research into the species' behavior and social organization
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Biotech Association Presses Agenda As National Elections Near
Franklin Hoke | May 24, 1992 | 4 min read
The next president--whoever it may be after elections this fall--must make the future of the biotechnology business a priority, according to a leading industry group. In a detailed agenda released late last month and forwarded to each major party's platform committees, the Industrial Biotechnology Association (IBA) identified the issues most important to its 130 members. "The highest-visibility issues for biotechnology this election surround health care reform and patent issues," says IBA dir
Industry vs Academia
The Scientist Staff | Apr 15, 2001 | 10+ min read
To conduct this survey, The Scientist invited 1800 readers via E-mail to respond to a web-based survey form. There were a total of 220 responses from March 2 to 12, 2001, a response rate of 12.2%. Have you held research positions in both academia and industry? (Positions may include graduate research, industrial internships, or any other research positions - paid or unpaid - in both work environments).   Percent Count Answers 72.6% 159/219 Yes 27.4% 60/219 No
An Honest Look at Biotech
Jennifer Rohn | Dec 1, 2010 | 6 min read
By Jennifer Rohn An Honest Look at Biotech Working at a start-up biotech company was so intriguing that it begged to become the subject of a novel. Jennifer Rohn; Photo: Richard Grant What is truth? For a life scientist in academia, the answer lies somewhere inside a ragged and incomplete sea of data. These data may or may not be “truths” that stand the test of time. The literature is, of course, littered with the corpses of debunked data tha
Flux and Uncertainty in the CRISPR Patent Landscape
Aggie Mika | Oct 1, 2017 | 10 min read
The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.

Run a Search

ADVERTISEMENT